Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001, a First-In-Class NMT Inhibitor, in Non-Hodgkin's Lymphomas and Solid Tumor Patients

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Edmonton, Alberta--(Newsfile Corp. - September 14, 2021) - To view the full announcement, including downloadable images, bios, and more, click here .

Metadata
Provider: 
NewsfileNewsfile
Retrieved on: 
Tuesday, September 14, 2021
Information
Tags: 
Safety, BC Cancer Agency, Patient, Cross Cancer Institute, Princess Margaret Hospital, Pharmaceutical industry
Geotags: 
Edmonton, Alberta, TORONTO, VANCOUVER
Organisation: 
REPORTABLE, INC.
Summary
Key Points: 
  • Edmonton, Alberta--(Newsfile Corp. - September 14, 2021) - To view the full announcement, including downloadable images, bios, and more, click here .
  • PCLX-001 is the first clinical candidate sponsored by Pacylex Pharmaceuticals to reach the clinical stage.
  • Upcoming enrollment of 20-30 patients to begin at the Cross Cancer Institute in Edmonton and expand to Princess Margaret Hospital in Toronto and the BC Cancer Agency in Vancouver.
  • This open label, dose escalation study will examine the safety and tolerability of PCLX-001.


Edmonton, Alberta--(Newsfile Corp. - September 14, 2021) - To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • PCLX-001 is the first clinical candidate sponsored by Pacylex Pharmaceuticals to reach the clinical stage.
  • Upcoming enrollment of 20-30 patients to begin at the Cross Cancer Institute in Edmonton and expand to Princess Margaret Hospital in Toronto and the BC Cancer Agency in Vancouver.
  • This open label, dose escalation study will examine the safety and tolerability of PCLX-001.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7294/96540_figure1_550.jpg

Click image above to view full announcement.

Contacts:

Michael Weickert Ph.D
650-218-1840
[email protected]

Source: Pacylex

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/96540

Copyright: 
copyright (c) newsfile corp. 2021. all rights reserved